169 related articles for article (PubMed ID: 26101574)
1. Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Fischmann T; Gibeau C; Kleinschek MA; Leccese E; Lesburg C; Maclean JK; Moy LY; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Steinhuebel D; Yang R
ACS Med Chem Lett; 2015 Jun; 6(6):683-8. PubMed ID: 26101574
[TBL] [Abstract][Full Text] [Related]
2. Identification of N-(1H-pyrazol-4-yl)carboxamide inhibitors of interleukin-1 receptor associated kinase 4: Bicyclic core modifications.
Lim J; Altman MD; Baker J; Brubaker JD; Chen H; Chen Y; Kleinschek MA; Li C; Liu D; Maclean JK; Mulrooney EF; Presland J; Rakhilina L; Smith GF; Yang R
Bioorg Med Chem Lett; 2015 Nov; 25(22):5384-8. PubMed ID: 26403930
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of N-(3-(4-[
Wang X; Xu W; Miao C; Dong F; Li W; Wang M; Gao M; Zheng QH; Xu Z
Appl Radiat Isot; 2018 Feb; 132():6-12. PubMed ID: 29127936
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction.
Inami H; Mizutani T; Watanabe J; Hayashida H; Ito T; Terasawa T; Kontani T; Yamagishi H; Usuda H; Aoyama N; Imamura E; Ishikawa T
Bioorg Med Chem; 2023 May; 87():117302. PubMed ID: 37201454
[TBL] [Abstract][Full Text] [Related]
6. Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
Chen Y; Tso K; Heckrodt TJ; Li H; Yen R; Lin N; Singh R; Taylor V; Masuda ES; Park G; Payan DG
Bioorg Med Chem Lett; 2022 Oct; 73():128900. PubMed ID: 35863718
[TBL] [Abstract][Full Text] [Related]
7. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
[TBL] [Abstract][Full Text] [Related]
8. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.
Chen Y; Singh R; Lin N; Taylor V; Masuda ES; Payan DG
ACS Med Chem Lett; 2022 Apr; 13(4):714-719. PubMed ID: 35450353
[TBL] [Abstract][Full Text] [Related]
10. The Discovery of 7-Isopropoxy-2-(1-methyl-2-oxabicyclo[2.1.1]hexan-4-yl)-
Evans R; Bolduc PN; Pfaffenbach M; Gao F; May-Dracka T; Fang T; Hopkins BT; Chodaparambil JV; Henry KL; Li P; Metrick C; Nelson A; Trapa P; Thomas A; Burkly L; Peterson EA
J Med Chem; 2024 Mar; 67(6):4676-4690. PubMed ID: 38467640
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system.
Azam MA; Dharanya L; Mehta CC; Sachdeva S
Acta Pharm; 2013 Mar; 63(1):19-30. PubMed ID: 23482310
[TBL] [Abstract][Full Text] [Related]
12. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
Genung NE; Guckian KM
Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
[TBL] [Abstract][Full Text] [Related]
14. Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
Tumey LN; Boschelli DH; Bhagirath N; Shim J; Murphy EA; Goodwin D; Bennett EM; Wang M; Lin LL; Press B; Shen M; Frisbie RK; Morgan P; Mohan S; Shin J; Rao VR
Bioorg Med Chem Lett; 2014 May; 24(9):2066-72. PubMed ID: 24726805
[TBL] [Abstract][Full Text] [Related]
15. Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4.
Seganish WM; McElroy WT; Herr RJ; Brumfield S; Greenlee WJ; Harding J; Komanduri V; Matasi J; Prakash KC; Tulshian D; Yang J; Yet L; Devito K; Fossetta J; Garlisi CG; Lundell D; Niu X; Sondey C
Bioorg Med Chem Lett; 2015 Aug; 25(16):3203-7. PubMed ID: 26115573
[TBL] [Abstract][Full Text] [Related]
16. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
Li X
Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
[TBL] [Abstract][Full Text] [Related]
17. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
[TBL] [Abstract][Full Text] [Related]
18. Synthetic studies towards isomeric pyrazolopyrimidines as potential ATP synthesis inhibitors of
Choi PJ; Lu GL; Sutherland HS; Giddens AC; Franzblau SG; Cooper CB; Denny WA; Palmer BD
Tetrahedron Lett; 2022 Feb; 90():None. PubMed ID: 35140452
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization and in vitro antimicrobial activity of novel fused pyrazolo[3,4-c]pyridazine, pyrazolo[3,4-d]pyrimidine, thieno[3,2-c]pyrazole and pyrazolo[3',4':4,5]thieno[2,3-d]pyrimidine derivatives.
Abdel Reheim MAM; Baker SM
Chem Cent J; 2017 Nov; 11(1):112. PubMed ID: 29098473
[TBL] [Abstract][Full Text] [Related]
20. Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.
Cumming IA; Degorce SL; Aagaard A; Braybrooke EL; Davies NL; Diène CR; Eatherton AJ; Felstead HR; Groombridge SD; Lenz EM; Li Y; Nai Y; Pearson S; Robb GR; Scott JS; Steward OR; Wu C; Xue Y; Zhang L; Zhang Y
Bioorg Med Chem; 2022 Jun; 63():116729. PubMed ID: 35439688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
